Irregular gastrointestinal drug absorption in Parkinson's disease.
about
The management of gastrointestinal symptoms in Parkinson's disease.Continuous drug delivery in Parkinson's disease.Can Patients with Parkinson's Disease Use Dry Powder Inhalers during Off Periods?Pharmacokinetics of levodopa, carbidopa, and 3-O-methyldopa following 16-hour jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson's disease patients.Conversion to IPX066 from Standard Levodopa Formulations in Advanced Parkinson's Disease: Experience in Clinical Trials.Gastric stasis in migraineurs: etiology, characteristics, and clinical and therapeutic implications.Levodopa-carbidopa enteral suspension in advanced Parkinson's disease: clinical evidence and experience.Delayed gastric emptying in Parkinson's disease.Unchanged gastric emptying and visceral perception in early Parkinson's disease after a high caloric test meal.Novel Approaches to Optimization of Levodopa Therapy for Parkinson's Disease.Pharmacokinetics of Rytary®, An Extended-Release Capsule Formulation of Carbidopa-Levodopa.Pharmacokinetics of levodopa/carbidopa delivered from gastric-retentive extended-release formulations in patients with Parkinson's disease.Apomorphine Subcutaneous Injection for the Management of Morning Akinesia in Parkinson's DiseaseGhrelin prevents levodopa-induced inhibition of gastric emptying and increases circulating levodopa in fasted rats.Motor fluctuations and Helicobacter pylori in Parkinson's disease.l-Dopa responsiveness is associated with distinctive connectivity patterns in advanced Parkinson's disease.Preclinical and clinical assessment of inhaled levodopa for OFF episodes in Parkinson's disease.Frequent administration of levodopa/carbidopa microtablets vs levodopa/carbidopa/entacapone in healthy volunteers.
P2860
Q34250597-FB0B8AC7-1A5D-4655-A715-1E3565FC774AQ34390800-3F6704B2-FB24-46DE-ADAA-6DEAC909C72CQ35691050-82B7C4B7-64F4-4770-B6EF-B033955F989EQ36910602-206C85DB-FBF3-42F9-9142-4810234CC5DAQ37054013-E6C8E264-71DF-49CF-8CF5-EACA60971920Q37398431-9D55197C-8860-4B53-BE86-CDAED59ACD82Q37698585-CFAC25F7-F2C5-43B1-B8F5-1C0FA3FCA892Q38154857-09BAED70-1BF4-4CF6-A416-03ED1CA86B34Q38410342-4793DFCE-0143-4562-AF2D-E046B2323707Q38742792-D4C7E83F-5C84-4D6F-ACF2-512427B397E4Q39150129-2BBDA1FD-64A8-451C-A3BB-434F8F74F520Q39746877-5F967947-7F3B-4470-8AA6-5E9B42EF3D67Q41849974-862852D4-15CC-45C6-9ED6-9528531A3E74Q42150469-933A900C-AADE-4826-ACBD-99C18E1CD19DQ45759430-E6C43B90-6D34-4A06-B012-324D57040C6CQ48636484-0081E62C-3C9F-4AE1-91AC-6F977504424EQ51442945-C1EDB9FA-C189-44B2-9656-BF0B4DC14E6DQ54295999-87D387E0-3888-4978-87A6-7EDE88EF17CC
P2860
Irregular gastrointestinal drug absorption in Parkinson's disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Irregular gastrointestinal drug absorption in Parkinson's disease.
@en
Irregular gastrointestinal drug absorption in Parkinson's disease.
@nl
type
label
Irregular gastrointestinal drug absorption in Parkinson's disease.
@en
Irregular gastrointestinal drug absorption in Parkinson's disease.
@nl
prefLabel
Irregular gastrointestinal drug absorption in Parkinson's disease.
@en
Irregular gastrointestinal drug absorption in Parkinson's disease.
@nl
P2860
P356
P1476
Irregular gastrointestinal drug absorption in Parkinson's disease.
@en
P2093
Dag Nyholm
Hans Lennernäs
P2860
P304
P356
10.1517/17425255.4.2.193
P407
P577
2008-02-01T00:00:00Z